Dr Sharon Discusses How Insurers Have Responded to the Availability of Therapies for RLS

In this video, Denise Sharon, MD, PhD, Clinical Director and Founding Partner, Comprehensive Sleep Medicine Center of the Gulf Coast, discusses how insurers have responded to the availability of therapies and changes in clinical practice guidelines for RLS.

Related Videos

Related Content

Advertisement

April 2nd 2025

How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care

Skylar Jeremias

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

April 2nd 2025

Areas of Unmet Need Continue to Burden Patients With gMG

Maggie L. Shaw

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

April 2nd 2025

The IRA’s Unintended Consequences for Drug Pricing and Coverage

Skylar Jeremias

The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.

April 1st 2025

New Studies Highlight JAK Inhibitors’ Power as AD Treatment

Skylar Jeremias

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis (AD), offering viable alternatives to systemic therapies.

Related Content

Advertisement

April 2nd 2025

How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care

Skylar Jeremias

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

April 2nd 2025

Areas of Unmet Need Continue to Burden Patients With gMG

Maggie L. Shaw

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

April 2nd 2025

The IRA’s Unintended Consequences for Drug Pricing and Coverage

Skylar Jeremias

The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.

April 1st 2025

New Studies Highlight JAK Inhibitors’ Power as AD Treatment

Skylar Jeremias

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis (AD), offering viable alternatives to systemic therapies.